Compare Johnson & Johnson (JNJ) vs Kyndryl Holdings Inc (KD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Kyndryl Holdings Inc — how do they compare? Johnson & Johnson trades at $261.04 (market cap $618.09B), while Kyndryl Holdings Inc trades at $11.7 (market cap $2.59B). The key difference: Johnson & Johnson is far larger — about 238.6× Kyndryl Holdings Inc's market cap, and Johnson & Johnson pays a 2.09% dividend while Kyndryl Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Kyndryl Holdings Inc for 36 Days on average.
| JNJ | KD | |
|---|---|---|
Market Cap | $618.09B | $2.59B |
Volume | 6,050,983 | 5,354,348 |
Sector | Health | Technology |
52-Week High | $278.43 | $29.76 |
52-Week Low | $186.00 | $10.59 |
Typical Hold Time | 129 Days | 36 Days |
Enterprise Value | $646.37B | $5.41B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Kyndryl (KD) trades at $11.67, up 1.92% today, with a bearish technical signal and neutral oscillators. The company reported a return to profitability in 2025 with net income of $252 million, though revenue has declined from $18.3B in 2022 to $15.1B. Recent news highlights a strategic focus on AI, including a new innovation lab and acquisitions, aiming to drive future growth amid competitive pressures.
The outlook is mixed: positive cash flow and low EV/EBITDA suggest value, but declining revenue and modest analyst consensus ($14.67 target) indicate caution. Key risks include execution on AI initiatives and sustained top-line pressure. Institutional sentiment is neutral with 71% hold ratings, reflecting a wait-and-see approach amid transformation efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →
